Prospective Registration of Head and Neck Cancer Patients for Clinical Data and Tissue Collection
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 2,000
- 试验地点
- 1
- 主要终点
- Progression-free survival
研究概览
简要总结
Head and neck cancers account for the sixth leading cause of cancers worldwide. The annual incidence of Head and neck cancers is more than 650,000 the patients each year. Head and neck cancers are associated with smoking, alcohol consumption, human papilloma virus (type 16 and 18) and previous exposure to radiation.
So far, most of clinical and research data about head and neck cancers, such as the etiology, pathogenesis, prognosis factors and associated factors, treatment outcomes, are from Western countries. However, due to various environmental factors, for example race, genetics, geographical factors, general hygiene and health care system differences, the possibility of differences of disease characteristics between Western and Asian people should be considered.
For several decades, there have been many studies about treatment modalities (surgery, chemotherapy, and radiation therapy), complications and side effects for head and neck cancers in the West. Many institutions tried to improve the survival rate and resolve the toxicity of chemotherapy and radiation treatment for head and neck cancer patients. However there has been little information about the characteristics of head and neck cancers, effectiveness of treatment (survival rate, recurrence, and complication rate), and prognosis, particularly in Korean as well as in Asian patients.
Therefore it is necessary to evaluate and analyze the features of head and neck cancers such as etiology, pathogenesis, risk factors, prognostic factors, treatment outcomes in a site specific cohort (South Korea) separately. It could be helpful to improve the treatment outcomes of head and neck cancers overall, to design race or site specific treatments for head and neck cancers, and to develop management strategy common in Asia as well as the West.
The purpose of this study is
- To establish the prospective tumor registry about patient's information, treatment-related morbidities, treatment outcomes and quality of life, in addition to the prospective collection of patient samples (blood and tumor tissues).
- To establish the predictive model for treatment outcomes and treatment-related morbidities.
- To develop the biomarkers as predictive and/or prognostic factors.
详细描述
Review of medical records Medical records of enrolled patients will be reviewed to evaluate clinical characteristics, treatment-related adverse events, time to progression and overall survival.
Behavioral : Questionnaires 3 times : Prior to the 1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment Other Names : Surveys
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults over 19 years-old
- •Patients diagnosed as head and neck cancer histopathologically according to American Joint Committee on Cancer, Cancer staging manual, 7th edition at Samsung Medical Center:
- •Comprise a part of head and neck
- •Oral cavity
- •Hypopharynx
- •Nasal cavity
- •Paranasal sinus
- •Nasopharynx
- •Salivary gland
- •Skin in the head and neck
- •In case patients are diagnosed at other hospitals, it can be possible to register the tissue of cancer cell with Samsung medical center and confirm the diagnosis by pathologists of Samsung medical center.
- •Histopathological type:
- •Squamous cell carcinoma
- •Malignant melanoma
- •Sarcoma and other carcinomas are included.
- •Metastasis of Unknown Origin (MUO) at head and neck is included.
- •Patients who receive a proper treatment as scheduled.
- •Informed consents: patients who understand the purpose of study and are capable of giving a written consent.
- •Exclusion criteria:
- •Patients who do not meet the requirements of inclusion criteria
排除标准
- 未提供
结局指标
主要结局
Progression-free survival
时间窗: 3 years
Revised RECIST guideline
次要结局
- Number of participants with treatment-related morbidity(5 years)
- Number of participants with treatment response(5 years)
- Scores of support survey(1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment)
- Overall survival(5 years)
- Quality of life score(1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment)
- Scores of distress questionnaire(1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment)
- Identification of biomarkers of clinical significance (prognostic)(5 years)
研究者
Han-Sin Jeong
Professor
Samsung Medical Center